Sanofi (Euronext: SAN, Nasdaq: SNY), a global healthcare leader, today announced it has entered into a definitive agreement to acquire Vigil Neuroscience, a U.S. biotech company focused on developing therapies for neurodegenerative diseases, in a transaction valued at approximately $470 million. The deal is Goodwin-led, with Goodwin Procter LLP serving as legal advisor to Vigil.
The acquisition strengthens Sanofi’s commitment to advancing innovation in neurology and expands its pipeline with the addition of VG-3927, a promising small-molecule candidate targeting Alzheimer’s disease. Sanofi previously invested $40 million in Vigil in June 2024, securing exclusive rights to VG-3927.
“Vigil’s cutting-edge science is highly complementary to our existing neurology capabilities,” said Houman Ashrafian, Head of Research and Development at Sanofi. “This acquisition reinforces our dedication to delivering innovative solutions that improve patients’ lives.”
Under the terms of the agreement, Sanofi will purchase all remaining outstanding shares of Vigil Neuroscience for $8.00 per share in cash upon closing, plus a contingent payment of $2.00 per share upon the first commercial sale of VG-3927. The transaction’s total equity value is approximately $600 million.
VG-3927 has demonstrated potential in preventing neural degeneration by activating key pathways in the brain. Through this acquisition, Sanofi gains full global rights to develop, manufacture, and commercialize the therapy.
The deal, expected to close by September 2025, is subject to customary closing conditions, including approval by Vigil’s shareholders. Vigil CEO Ivana Magovčević-Liebisch, Chair Bruce Booth, and Atlas Venture—collectively holding 16% of the company’s shares—have agreed to vote in favor of the transaction.
Centerview Partners LLC is serving as financial advisor to Vigil. Legal counsel for Sanofi was not disclosed.
